Form 4: PAHC CEO Jack Bendheim Sells Shares, Converts Stock

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC reported sales of Class A Common Stock and conversion of Class B shares into Class A shares under a 10b5-1 plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC (also a 10% owner), reported transactions in Class A Common Stock and Class B Common Stock.
• On October 17, 2025, BFI Co., LLC sold 700 shares of Class A Common Stock at a weighted average price of $40.0319 per share.
• On October 20, 2025, BFI Co., LLC sold 16,075 shares of Class A Common Stock at a weighted average price of $40.3842 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On October 21, 2025, BFI Co., LLC converted 50,000 shares of Class B Common Stock into 50,000 shares of Class A Common Stock at an exercise price of $0.
• Following these transactions, BFI Co., LLC beneficially owns 73,899 shares of Class A Common Stock indirectly.
• Jack Bendheim directly holds 16,840 shares of Class A Common Stock.
• BFI Co., LLC also beneficially owns 20,086,034 shares of Class B Common Stock indirectly, which are convertible into Class A Common Stock on a one-for-one basis.

Sentiment

Score: 5

Explanation: While insider selling can be perceived negatively, the existence of a Rule 10b5-1 plan mitigates concerns that the sales are based on negative undisclosed information. The conversion of Class B to Class A is a routine corporate action, leading to a neutral sentiment.

Positives

• The reported sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were not reactive to recent company performance or undisclosed information.

Negatives

• Significant insider selling of Class A Common Stock by a key executive and a related entity, totaling 16,775 shares, could be perceived negatively by investors.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports insider transactions.

Industry Context

This filing reports insider transactions and does not provide information directly related to broader industry trends or competitors.

Related Party Transactions

• BFI Co., LLC, which conducted the sales and conversion, is an entity over which Jack Bendheim (President and CEO, Director, 10% Owner) exercises voting and dispositive power. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider selling, even if pre-planned, as a signal, potentially influencing investor sentiment regarding the company's stock.

Key Dates

Recommendation

The filing reports insider transactions, specifically sales by the CEO and a related entity. While insider selling can sometimes signal a lack of confidence, these sales were conducted under a Rule 10b5-1 trading plan, suggesting they were pre-scheduled and not based on new, negative material information. The conversion of Class B to Class A stock is a routine event. Without additional financial or operational context, a 'Hold' recommendation is appropriate, as the transactions themselves do not provide a strong basis for a 'Buy' or 'Sell' decision. Investors should consider the company's broader financial performance and strategic outlook.

Keywords

Phibro Animal Health Corp, PAHC, Jack Bendheim, BFI Co. LLC, Insider Trading, Form 4, Stock Sale, Class A Common Stock, Class B Common Stock, 10b5-1 plan, CEO, Director, 10% Owner